相关实验视频

Updated: Jun 5, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

淋巴切除术在晚期卵巢癌中的作用:一个元分析

Carlo Ronsini¹, Francesca Pasanisi¹, Giada Andreoli¹

¹Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

Frontiers in surgery

|December 12, 2024

概括

淋巴切除术通过降低死亡风险,改善了晚期卵巢癌患者的整体生存率. 这种外科手术方法显示出一种保护作用,尽管无病生存率仍然相当.

科学领域:

妇科瘤学妇科瘤学
手术瘤学手术瘤学
基于证据的医学基于证据的医学.

背景情况:

表皮卵巢癌 (EOC) 是妇科癌症死亡率的主要原因.
腹和淋巴扩散是EOC中转移的主要途径.
淋巴结的参与是常见的,发生在48-75%的晚期卵巢癌 (ASOC) 病例中.

研究的目的:

系统地审查和分析ASOC中关于淋巴切除术的当前文献.
研究淋巴切除术对ASOC患者生存结果的影响.

主要方法:

按照PRISMA指南,对PubMed和Scopus数据库进行系统的文献搜索 (2022年6月).
包括报告无疾病生存率 (DFS) 和总生存率 (OS) 数据的比较研究.
在ASOC.中比较淋巴切除术与避免淋巴切除术的元分析.

主要成果:

18项研究和26965名患者被纳入了分析.
淋巴切除术与统计学上显著的更高整体存活率 (OS) 相关 (RR 1.31,p < .00001).
在无病生存期 (DFS) 中没有观察到统计学上显著的差异 (RR 1.23,p = 0.25).

结论:

淋巴切除术表明在晚期卵巢癌中起着保护作用.
该程序与死亡风险的显著降低有关.
登记号:PROSPERO CRD42022341646. 登记号:PROSPERO CRD42022341646. 登记号:PROSPERO CRD42022341646. 登记号:PROSPERO CRD42022341646. 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO 登记号:PROSPERO

关键词:

一个先进的阶段,先进的阶段.没有疾病的生存率.淋巴腺切除术是指淋巴腺切除术.卵巢癌是发生在卵巢的癌症.总体存活率总体存活率

更多相关视频

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...